 Shares of Abiomed Inc. ABMD, -2.32 rocketed 48.8 toward a 14-month high in premarket trading Tuesday, after the provider of medical technology that supports circulation and oxygenation agreed to acquired by Johnson Johnson JNJ, -0.51 in a deal valued at 16.6 billion. Under terms of the deal, JJ will pay upfront 380 in cash for each Abiomed share outstanding, which represents a 50.7 premium to Mondays closing price of 252.08. 